Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityActive in the last 2 years

Liang Han

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3268-5214; OpenAlex author ID A5101965701. Sources: OpenAlex.

Their work

Papers
19 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
43
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 3 papers · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 2 papers

Papers 19

  1. NEAT1 promotes the perineural invasion of pancreatic cancer via the E2F1/GDNF axis. Co-author DOI 10.1016/j.canlet.2025.217497↗
  2. Chlorophyllin exerts synergistic anti-tumor effect with gemcitabine in pancreatic cancer by inducing cuproptosis. Co-author DOI 10.1186/s10020-025-01180-y↗
  3. Analysis of chemoresistance characteristics and prognostic relevance of postoperative gemcitabine adjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1002/cam4.7229↗
  4. HGF/c-Met pathway facilitates the perineural invasion of pancreatic cancer by activating the mTOR/NGF axis. Co-author DOI 10.1038/s41419-022-04799-5↗
  5. Arl4c promotes the growth and drug resistance of pancreatic cancer by regulating tumor-stromal interactions. Co-author DOI 10.1016/j.isci.2021.103400↗
  6. NGF from pancreatic stellate cells induces pancreatic cancer proliferation and invasion by PI3K/AKT/GSK signal pathway. Last author DOI 10.1111/jcmm.15265↗
  7. Cav-1 Ablation in Pancreatic Stellate Cells Promotes Pancreatic Cancer Growth through Nrf2-Induced shh Signaling. Co-author DOI 10.1155/2020/1868764↗
  8. EIF5A regulates proliferation and chemoresistance in pancreatic cancer through the sHH signalling pathway. Last author DOI 10.1111/jcmm.14167↗
  9. Curcumin attenuates hyperglycemia-driven EGF-induced invasive and migratory abilities of pancreatic cancer via suppression of the ERK and AKT pathways. Co-author DOI 10.3892/or.2018.6833↗
  10. Hyperglycemia aggravates microenvironment hypoxia and promotes the metastatic ability of pancreatic cancer. Co-author DOI 10.1016/j.csbj.2018.10.006↗
  11. The inhibition of heme oxygenase-1 enhances the chemosensitivity and suppresses the proliferation of pancreatic cancer cells through the SHH signaling pathway. Co-author DOI 10.3892/ijo.2018.4363↗
  12. Overexpression of Gremlin 1 by sonic hedgehog signaling promotes pancreatic cancer progression. Co-author DOI 10.3892/ijo.2018.4573↗
  13. Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2016.10.019↗
  14. Lipoxin A4 reverses mesenchymal phenotypes to attenuate invasion and metastasis via the inhibition of autocrine TGF-β1 signaling in pancreatic cancer. Co-author DOI 10.1186/s13046-017-0655-5↗
  15. Pancreatic stellate cells contribute pancreatic cancer pain via activation of sHH signaling pathway. Co-author DOI 10.18632/oncotarget.7776↗
  16. Stromal-derived factor-1α/CXCL12-CXCR4 chemotactic pathway promotes perineural invasion in pancreatic cancer. Co-author DOI 10.18632/oncotarget.3069↗
  17. Sonic hedgehog paracrine signaling activates stromal cells to promote perineural invasion in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-13-3426↗
  18. The Activation of β1-integrin by Type I Collagen Coupling with the Hedgehog Pathway Promotes the Epithelial-Mesenchymal Transition in Pancreatic Cancer. Co-author DOI 10.2174/1568009614666140402105101↗
  19. Indometacin ameliorates high glucose-induced proliferation and invasion via modulation of e-cadherin in pancreatic cancer cells. Co-author DOI 10.2174/09298673113209990249↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 15 shared papers, 2013–2025 · strength 1.30
  2. Zheng Wu · 8 shared papers, 2015–2025 · strength 0.95
  3. Wanxing Duan · 10 shared papers, 2013–2025 · strength 0.83
  4. Weikun Qian · 6 shared papers, 2018–2025 · strength 0.78
  5. Jiguang Ma · 10 shared papers, 2013–2025 · strength 0.71
  6. Tao Qin · 4 shared papers, 2018–2025 · strength 0.57
  7. Zheng Wang · 7 shared papers, 2014–2022 · strength 0.54
  8. Jiantao Mo · 2 shared papers, 2025 · strength 0.49
  9. Shuai Wu · 2 shared papers, 2024–2025 · strength 0.46
  10. Jiaqiang Ren · 2 shared papers, 2024–2025 · strength 0.46
  11. Zheng Wang · 3 shared papers, 2019–2021 · strength 0.40
  12. Qinhong Xu · 8 shared papers, 2013–2018 · strength 0.39
  13. Wei Li · 5 shared papers, 2013–2021 · strength 0.38
  14. Jianjun Lei · 7 shared papers, 2014–2020 · strength 0.38
  15. Xuqi Li · 7 shared papers, 2014–2020 · strength 0.38
  16. Zheng Wang · 2 shared papers, 2019–2025 · strength 0.35
  17. Erxi Wu · 7 shared papers, 2013–2020 · strength 0.35
  18. Ying Xiao · 3 shared papers, 2018–2022 · strength 0.35
  19. Jie Jiang · 2 shared papers, 2019–2020 · strength 0.27
  20. Tao Qin · 2 shared papers, 2019–2020 · strength 0.27
  21. Jingtao Gu · 1 shared paper, 2025 · strength 0.25
  22. Jie Li · 1 shared paper, 2024 · strength 0.22
  23. Zhenhua Ma · 4 shared papers, 2014–2017 · strength 0.18
  24. Liang Cheng · 2 shared papers, 2018 · strength 0.16
  25. Bin Yan · 2 shared papers, 2018 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.